ALLO‑CEL
Multiple solid & liquid tumors (allogeneic)
Pre‑clinical / IND filingActive
Key Facts
Indication
Multiple solid & liquid tumors (allogeneic)
Phase
Pre‑clinical / IND filing
Status
Active
Company
About Biosyngen
Biosyngen builds first‑in‑class cell‑therapy platforms to treat solid‑tumor cancers with rapid, safe, and scalable manufacturing.
View full company profile